m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03543
 [1], [2]
Histone modification H3K27ac EP300 LINC01605 Indirect Enhancement m6A modification MAPK14 MAPK14 METTL3 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Mitogen-activated protein kinase 14 (p38/MAPK14)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone acetyltransferase p300 (P300) WRITER View Details
Regulated Target Histone H3 lysine 27 acetylation (H3K27ac) View Details
Downstream Gene LINC01605 View Details
Crosstalk Relationship Histone modification  →  m6A Enhancement
Crosstalk Mechanism histone modification indirectly regulates m6A modification through downstream signaling pathways
Crosstalk Summary LINC01605 was regulated by SMYD2-p300-mediated modifications of histone H3K4me3 as well as Histone H3 lysine 27 acetylation (H3K27ac). LINC01605 was found to bind to METTL3 and promote the m6A modification of SPTBN2 mRNA, thereby facilitating the translation of SPTBN2. METTL3 played a tumor-suppressive role in Colorectal cancer cell proliferation, migration and invasion through Mitogen-activated protein kinase 14 (p38/MAPK14)/ERK pathways, which indicated that METTL3 was a novel marker for CRC carcinogenesis, progression and survival.
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Pathway Response MAPK signaling pathway hsa04010
Cell Process Cell proliferation
Cell migration
Cell invasion
In-vitro Model
 HCT 116 Colon carcinoma Homo sapiens CVCL_0291
DLD-1 Colon adenocarcinoma Homo sapiens CVCL_0248
KM12 Colon carcinoma Homo sapiens CVCL_1331
HCT 8 Colon adenocarcinoma Homo sapiens CVCL_2478
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Histone acetyltransferase p300 (P300) 2 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name CCS1477 Phase 1/2 [3]
Synonyms
CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 134457551
TTD: DIY4C2
 Compound Name FT-7051 Phase 1 [4]
MOA Inhibitor
External Link
TTD: DT8IL6
Mitogen-activated protein kinase 14 (p38/MAPK14) 75 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Ozagrel Phase 4 [5]
Synonyms
Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5282440
TTD: D0C7AA
DrugBank: DB12017
 Compound Name Losmapimod Phase 3 [5]
Synonyms
585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod pound> HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 7.943 nM
External Link
CID: 11552706
TTD: D0C8DD
DrugBank: DB12270
 Compound Name VX-702 Phase 2a [6]
Synonyms
ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide
    Click to Show/Hide
MOA Modulator
External Link
CID: 10341154
TTD: D0D9AH
DrugBank: DB05470
 Compound Name Dilmapimod Phase 2 [5]
Synonyms
SB-681323; 444606-18-2; UNII-Q3238VQW0N; GW 681323; SB 681323; Q3238VQW0N; GW681323; SB681323; Dilmapimod [USAN:INN]; GSK 681323; Dilmapimod (USAN/INN); GTPL7815; SCHEMBL1065268; CHEMBL2103838; ORVNHOYNEHYKJG-UHFFFAOYSA-N; BCP23819; ZINC34997404; CS-6731; DB12140; SB16737; 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; HY-10404; GW-681323; DB-070558; FT-0718750; J3.498.915J; D09602
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10297982
TTD: D0K0JQ
DrugBank: DB12140
 Compound Name VX-745 Phase 2 [7]
Synonyms
5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 70 nM
External Link
CID: 3038525
TTD: D02NNV
DrugBank: DB07138
 Compound Name PMID25991433-Compound-O2 Patented [8]
MOA Inhibitor
External Link
TTD: D03JFK
 Compound Name PMID25991433-Compound-L2 Patented [8]
MOA Inhibitor
Activity IC50 > 5000 nM
External Link
TTD: D08OJQ
 Compound Name PMID25991433-Compound-L3 Patented [8]
MOA Inhibitor
Activity IC50 > 10000 nM
External Link
TTD: D0G7LB
 Compound Name PMID25991433-Compound-L1 Patented [8]
MOA Inhibitor
Activity IC50 = 190 nM
External Link
TTD: D0Q8CR
 Compound Name PMID25991433-Compound-F2 Patented [8]
MOA Inhibitor
Activity IC50 = 3400 nM
External Link
TTD: D06JRV
 Compound Name PMID25991433-Compound-A1 Patented [8]
MOA Inhibitor
Activity IC50 < 10000 nM
External Link
TTD: D0H4HD
 Compound Name PAMAPIMOD Discontinued in Phase 2 [9]
Synonyms
449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 14 nM
External Link
CID: 16220188
TTD: D04WCI
 Compound Name R-1487 Discontinued in Phase 1 [10]
Synonyms
449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 nM
External Link
CID: 11406590
TTD: D04YHW
DrugBank: DB06518
 Compound Name FR167653 Discontinued in Phase 1 [11]
Synonyms
HMPQTEPEMQZWQH-ROUUACIJSA-N; 2-(5-AMINO-6-OXO-2-PHENYL-6H-PYRIMIDIN-1-YL)-N-[2-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-1-(METHYLETHYL)-2-HYDROXYETHYL]ACETAMIDE; AC1NR9VL; SCHEMBL15034365; 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-N-[(1S,2S)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide; ONO-6818
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 135484078
TTD: D05QMG
 Compound Name SB-242235 Discontinued in Phase 1 [12]
Synonyms
193746-75-7; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 19 nM
External Link
CID: 9863367
TTD: D0A9KI
 Compound Name SB 235699 Discontinued in Phase 1 [7]
Synonyms
4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; VK-19911; CHEMBL279416; UNII-NP7J08ZRYY; NP7J08ZRYY; 180869-32-3; SCHEMBL140202; HEP 689; sb235699; BDBM50099331; SB-235699; 4-(5-(4-Fluorophenyl)-3-(4-piperidyl)imidazol-4-yl)pyridine; Pyridine, 4-(4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl)-
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 38 nM
External Link
CID: 9797240
TTD: D0W0AM
 Compound Name SC-102 Terminated [13]
Synonyms
4-[3-(4-Fluorophenyl)-1h-Pyrazol-4-Yl]pyridine; 3hvc; GG5; SCHEMBL1554633; CHEMBL1233024; BDBM19429; BILJSHVAAVZERY-UHFFFAOYSA-N; ZINC16052350; DB07829; 5-(4-Fluorophenyl)-4-(pyridin-4-yl)pyrazole; 4-[3-(4-Fluorophenyl)-1H-pyrazole-4-yl]pyridine; 4-(3-(4-fluorophenyl)-1h-pyrazol-4-yl); SPC-0038B; SPC-0172; Temoporfin derivatives (cancer); Temoporfin derivatives (cancer), Scotia Holdings
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 67 nM
External Link
CID: 12106168
TTD: D0O7BW
DrugBank: DB07829
 Compound Name SB220025 Terminated [14]
Synonyms
3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 19 nM
External Link
CID: 5164
TTD: D09ICC
DrugBank: DB04338
 Compound Name SB 203580 Terminated [15]
Synonyms
152121-47-6; SB-203580; SB203580; 4-(4-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine; 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole; CHEBI:90705; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; CHEMBL10; RWJ 64809; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; PB 203580; UNII-WS78QR6DSV
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 nM
External Link
CID: 176155
TTD: D0F8DL
 Compound Name 9-Benzyl-6-phenylsulfanyl-9H-purine Investigative [16]
Synonyms
SCHEMBL6662063
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11347708
TTD: D00ODN
 Compound Name N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide Investigative [17]
Synonyms
CHEMBL198563
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 450 nM
External Link
CID: 11703439
TTD: D00PPB
 Compound Name UCB-1277763 Investigative [18]
Synonyms
P38 kinase inhibitors (inflammation), UCB
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D00YRF
 Compound Name Small molecule 34 Investigative [14]
Synonyms
3-(2-(4-pyridyl)ethyl)indole; 3-(2-PYRIDIN-4-YLETHYL)-1H-INDOLE; INHIBITOR OF P38 KINASE; 3-(2-(Pyridin-4-yl)ethyl)-1H-indole; 3-[2-(pyridin-4-yl)ethyl]-1H-indole; 3-(2-Pyridin-4-yl-ethyl)-1H-indole; L12; Maybridge1_000718; Cambridge id 5373101; AC1L1E9J; Oprea1_574113; Oprea1_420786; SCHEMBL735580; CHEMBL193156; HMS543I14; ZINC94256; BDBM13346; UUEYCHLWAOBOHG-UHFFFAOYSA-N; 1w84; MolPort-001-886-488; HMS3604M06; 3-[2-(4-pyridyl)-ethyl]-indole; STL328644; CCG-45397; 3-[2-(4-Pyridyl)ethyl]-1H-indole; AKOS000545583; MCULE-4657429599
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 27934
TTD: D01CRK
DrugBank: DB01953
 Compound Name SB-218655 Investigative [19]
Synonyms
1bmk; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyrimidin-2-amine; 4-(FLUOROPHENYL)-1-CYCLOPROPYLMETHYL-5-(2-AMINO-4-PYRIMIDINYL)IMIDAZOLE; 165806-51-9; SB 218655; C14316; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine; SB5; AC1L1JRC; AC1Q4ON9; SCHEMBL4323457; CHEMBL590753; BDBM15238; CTK4D2173; DTXSID50274456; sb218655; AKOS030547879
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 25 nM
External Link
CID: 5172
TTD: D02NKV
DrugBank: DB03980
 Compound Name 9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine Investigative [16]
Synonyms
SCHEMBL6659707
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11336624
TTD: D03XYK
 Compound Name 6-Phenylsulfanyl-9H-purine Investigative [16]
Synonyms
Purine, 6-(phenylthio)-; 6-(Phenylthio)purine; 1H-Purine, 6-(phenylthio)-; 5450-35-1; NSC 15746; UNII-3KH11DU8DY; 6-phenylsulfanyl-7H-purine; BRN 0013668; 3KH11DU8DY; AI3-52068; AC1Q4XUH; AC1L3TI0; 4-26-00-01985 (Beilstein Handbook Reference); 9H-Purine,6-(phenylthio)-; SCHEMBL796397; 6-(phenylsulfanyl)-7H-purine; CHEMBL175600; 9H-Purine, 6-(phenylthio)-; CTK5A1336; DTXSID20202908; NSC15746; ZINC13608565; NSC-15746; AKOS030562402
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 95065
TTD: D04CRB
 Compound Name Talmapimod Investigative [20]
Synonyms
SCIO-469; 309913-83-5; Scios 469; UNII-B1E00KQ6NT; SCIO 469; B1E00KQ6NT; CHEMBL514201; SCIO 469 hydrochloride; CHEBI:90683; Talmapimod hydrochloride; 2-(6-Chloro-5-{[(2r,5s)-4-(4-Fluorobenzyl)-2,5-Dimethylpiperazin-1-Yl]carbonyl}-1-Methyl-1h-Indol-3-Yl)-N,N-Dimethyl-2-Oxoacetamide; 2-[6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine-1-carbonyl]-1-methylindol-3-yl]-N,N-dimethyl-2-oxoacetamide; 750646-72-1; Talmapimod [USAN]; Talmapimod [USAN:INN]
    Click to Show/Hide
MOA Modulator
Activity IC50 = 96 nM
External Link
CID: 9871074
TTD: D04HWF
DrugBank: DB05412
 Compound Name N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide Investigative [21]
Synonyms
CHEMBL1091737
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1260 nM
External Link
CID: 46886448
TTD: D07TTR
 Compound Name Dihydro-quinolinone Investigative [19]
Synonyms
553-03-7; 3,4-Dihydro-2(1H)-quinolinone; 3,4-Dihydroquinolin-2(1H)-one; Hydrocarbostyril; 1,2,3,4-tetrahydroquinolin-2-one; 3,4-Dihydrocarbostyril; 3,4-dihydro-1H-quinolin-2-one; 2-Oxo-1,2,3,4-tetrahydroquinoline; 3,4-Dihydro-2-quinolinol; o-Aminohydrocinnamic acid lactam; UNII-2CKG6TX32F; 3,4-Dihydro-2(1H)quinolinone; 2(1H)-Quinolinone, 3,4-dihydro-; NSC 49170; 2CKG6TX32F; CHEMBL388582; TZOYXRMEFDYWDQ-UHFFFAOYSA-N; 3,4-DIHYDRO-2-QUINOLONE; MFCD00016722; 3,4-Dihydro-2(1H)-quinolinone, 98%
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.74 nM
External Link
CID: 64796
TTD: D08BIP
 Compound Name (5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone Investigative [22]
Synonyms
54606-37-0; (5-Amino-1-phenyl-1H-pyrazol-4-yl)phenyl methanone; (5-AMINO-1-PHENYL-1H-PYRAZOL-4-YL)(PHENYL)METHANONE; 4-benzoyl-5-aminopyrazole 1; CHEMBL203333; (5-amino-1-phenyl-1H-pyrazol-4-yl)-phenyl-methanone; SCHEMBL13662120; BDBM15714; 5-amino-4-benzoyl-1-phenylpyrazole; ZINC12365464; 1-Phenyl-4-benzoyl-1H-pyrazol-5-amine; 4-benzoyl-1-phenyl-1H-pyrazol-5-amine; KB-208557; FT-0728731; (5-Amino-1-phenyl-1H-pyrazol-4-yl)(phenyl)methanone, AldrichCPR
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 570 nM
External Link
CID: 15311937
TTD: D08WFC
 Compound Name 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE Investigative [13]
Synonyms
3-(naphthalen-1-ylmethoxy)pyridin-2-amine; 2-amino-3-(1-naphthylmethyloxy)pyridine; LI4; 1wbw; CHEMBL195393; AC1NS185; SCHEMBL6080116; BDBM13340; AKOS009255557; DB08093; Pyridine derived fragment based inhibitor 5
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5326871
TTD: D09GQO
DrugBank: DB08093
 Compound Name PMID22521646C12 Investigative [23]
Synonyms
GTPL8125; BDBM50420761
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25060878
TTD: D09OKU
 Compound Name N-(4-methyl-benzyl)-4-phenoxy-benzamide Investigative [17]
Synonyms
CHEMBL199174; AC1OVMY0; BDBM50174096
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1600 nM
External Link
CID: 7916852
TTD: D09XVY
 Compound Name 2-Chlorophenol Investigative [14]
Synonyms
o-Chlorophenol; 95-57-8; Phenol, 2-chloro-; 2-Hydroxychlorobenzene; o-Chlorphenol; o-Chlorophenic acid; Phenol, o-chloro-; 2-Chloro-1-hydroxybenzene; CHLOROPHENOL; Septi-Kleen; 2-chloro-phenol; RCRA waste number U048; Pine-O Disinfectant; Caswell No. 203; o-Chlorphenol [German]; UNII-K9KAV4K6BN; Phenol, chloro-; NSC 2870; CCRIS 640; HSDB 1415; EINECS 202-433-2; K9KAV4K6BN; RCRA waste no. U048; 1-Chloro-2-hydroxybenzene; EPA Pesticide Chemical Code 062204; AI3-09060; CHEBI:47083; ISPYQTSUDJAMAB-UHFFFAOYSA-N
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 7245
TTD: D09ZZI
DrugBank: DB03110
 Compound Name GSK-280 Investigative [18]
Synonyms
P38 kinase inhibitors (inflammation), GSK
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0DK2X
 Compound Name SB-216995 Investigative [19]
Synonyms
PYRIDINYLIMIDAZOLE; CHEMBL96741; sb216995; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyridine; 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE; SB6; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyridine; 1bl6; AC1L1JR9; SCHEMBL4915662; CTK7C0283; BDBM15237; ZINC2047872; DB08522
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 160 nM
External Link
CID: 5171
TTD: D0E4LU
DrugBank: DB08522
 Compound Name N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide Investigative [17]
Synonyms
CHEMBL199074
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1400 nM
External Link
CID: 44405448
TTD: D0H8RU
 Compound Name PHA-666859 Investigative [18]
Synonyms
SC-409; SD-0006; P38-alpha kinase inhibitor (inflammation/diabetic retinopathy); P38-alpha kinase inhibitor (inflammation/diabetic retinopathy), Pfizer
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0L1NU
 Compound Name 9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine Investigative [16]
Synonyms
CHEMBL176245
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11175093
TTD: D0L3DF
 Compound Name SB-227931 Investigative [24]
Synonyms
CHEMBL371720; BDBM50173166
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 46 nM
External Link
CID: 44404442
TTD: D0M2OL
 Compound Name N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide Investigative [17]
Synonyms
CHEMBL198832
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 600 nM
External Link
CID: 44405454
TTD: D0N9HX
 Compound Name 6-(4-Fluoro-phenylsulfanyl)-9H-purine Investigative [16]
Synonyms
6-(4-fluorophenylsulfanyl)-9H-purine; 736142-69-1; CHEMBL175603
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11265091
TTD: D0Q8HM
 Compound Name 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE Investigative [13]
Synonyms
CHEMBL199237; CHEBI:41135; 4-phenoxy-N-[(pyridin-2-yl)methyl]benzamide; BI5; 1zyj; AC1M5EGY; Oprea1_773674; MolPort-004-000-036; HMS3604L15; BDBM50174097; ZINC13284470; AKOS027682522; MCULE-5005773275; DB07459; Z30166389
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1500 nM
External Link
CID: 2352168
TTD: D0QS9T
DrugBank: DB07459
 Compound Name DP-802 Investigative [18]
Synonyms
P38-alpha inhibitors (inflammation); P38-alpha inhibitors (inflammation), Deciphera
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0S4BP
 Compound Name Ro-3201195 Investigative [25]
Synonyms
[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE; CHEMBL203567; CHEBI:45116; Ro 320-1195; 2gfs; PQB; [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl](3-{[(2S)-2,3-dihydroxypropyl]oxy}phenyl)methanone; aminopyrazole 63; RO3201195; AC1NS1L4; SCHEMBL4108597; BDBM15754; IJDQETGUEUJVTB-HNNXBMFYSA-N; DB08424; Ro-320-1195; J3.504.577E; UNII-TE3ESF890C component IJDQETGUEUJVTB-HNNXBMFYSA-N; 5-amino-1-(4-fluorophenyl)-4-[3-{2(S),3-dihydroxypropoxy}benzoyl]pyrazole
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 250 nM
External Link
CID: 5327067
TTD: D0S6GE
DrugBank: DB08424
 Compound Name 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine Investigative [26]
Synonyms
CHEMBL198334; BDBM50173628
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 15 nM
External Link
CID: 11277481
TTD: D0S9SX
 Compound Name Triazolopyridine Investigative [13]
Synonyms
CP-808844; 6-[4-(4-FLUOROPHENYL)-1,3-OXAZOL-5-YL]-3-ISOPROPYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE; 1zzl; AC1NRDFA; Triazolopyridine deriv. 25; SCHEMBL40860; CHEMBL194322; BDBM15414; DB04797; 6-[4-(4-fluorophenyl)-1,3-oxazol-5-yl]-3-(1-methylethyl)[1,2,4]triazolo[4,3-a]pyridine; 6-[4-(4-Fluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine; 4-(4-fluorophenyl)-5-[3-(propan-2-yl)-[1,2,4]triazolo[3,4-a]pyridin-6-yl]-1,3-oxazole
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5 nM
External Link
CID: 5289514
TTD: D0X5CM
DrugBank: DB04797
 Compound Name 3-(Benzyloxy)Pyridin-2-Amine Investigative [14]
Synonyms
2-Amino-3-benzyloxypyridine; 24016-03-3; 3-Benzyloxy-2-pyridylamine; 2-Pyridinamine, 3-(phenylmethoxy)-; 3-benzyloxypyridin-2-amine; 3-Benzyloxy-2-aminopyridine; 2-amino-3-benzyloxy pyridine; 3-phenylmethoxypyridin-2-amine; 2-Amino-3-(benzyloxy)pyridine; 3-(phenylmethoxy)-2-pyridinamine; MFCD00006316; 3IP; 3-(phenylmethoxy)-2-pyridylamine; 2-Amino-3-benzyloxypyridine, 98.5%; 3-(benzyloxy)pyridin-2-amin; 3fty; EINECS 245-983-9; PubChem2575; 1w7h; ACMC-1COKO; AC1L3JRI; Maybridge1_001801; AC1Q52WQ
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100000 nM
External Link
CID: 90334
TTD: D09DRF
DrugBank: DB02352
 Compound Name 6-Benzylsulfanyl-9H-purine Investigative [16]
Synonyms
Purine, 6-(benzylthio)-; 6-Benzothiopurine; 6-Benzyl MP; 724-34-5; 6-(Benzylthio)purine; 6-Benzylmercaptopurine; 6-Benzyl-MP; SRI 673; NSC 29421; 6-(benzylsulfanyl)-9H-purine; Purine, 6-benzylthio-; 6-((Phenylmethyl)thio)-1H-purine; EINECS 211-965-4; 6-(benzylthio)-9H-purine; AI3-50277; 6-[BENZYLTHIO]-1H-PURINE; 1H-Purine, 6-[(phenylmethyl)thio]-; 1H-Purine, 6-((phenylmethyl)thio)-; 6-[(PHENYLMETHYL)THIO]-1H-PURINE; 6-benzylthiopurine; AC1Q4XUO; CBMicro_000185; 6-(phenylmethylthio)purine
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 93558
TTD: D0BH7S
 Compound Name Phenyl-(3-phenyl-1H-indazol-6-yl)-amine Investigative [27]
Synonyms
CHEMBL383177; N,3-diphenyl-1H-indazol-6-amine; SCHEMBL6582340
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 30 nM
External Link
CID: 10236389
TTD: D0H2PE
 Compound Name IN-1130 Investigative [28]
Synonyms
UNII-KW4O83PQ97; 868612-83-3; CHEMBL492634; KW4O83PQ97; IN 1130; SCHEMBL139815; MolPort-042-665-839; ZINC13985930; BDBM50252542; AKOS032962854; Benzamide, 3-((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; Benzamide, 3-((4-(6-methyl-2-pyridinyl)-5-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; NCGC00386726-01; KB-274188; 3-[[5-(6-Methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 480 nM
External Link
CID: 11676119
TTD: D0K6YK
 Compound Name 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine Investigative [16]
Synonyms
4-(Phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine; 736142-84-0; 7h-pyrrolo[2,3-d]pyrimidine,4-(phenylthio)-; SCHEMBL191691; CHEMBL360302; TUBUPSQEQADRHY-UHFFFAOYSA-N; ZINC13608572; KB-270401; 7H-Pyrrolo[2,3-d]pyrimidine, 4-(phenylthio)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11481564
TTD: D0M3CT
 Compound Name Tyrphostin ag-1478 Investigative [29]
Synonyms
AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 560 nM
External Link
CID: 2051
TTD: D0ZH1U
 Compound Name RWJ-68354 Investigative [30]
Synonyms
CHEMBL115769; 2-(4-FLUOROPHENYL)-4-METHOXY-3-(PYRIDIN-4-YL)-1H-PYRROLO[2,3-B]PYRIDIN-6-AMINE; rwj68354; SCHEMBL149547; BDBM15457; BDBM50215267; AKOS000280165
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 52 nM
External Link
CID: 9819053
TTD: D06NUL
 Compound Name GW-788388 Investigative [31]
Synonyms
452342-67-5; GW788388; 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide; GW 788388; UNII-N14114957J; CHEMBL202887; N14114957J; 4-[4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl]-N-(tetrahydropyran-4-yl)benzamide; N-(oxan-4-yl)-4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}benzamide; 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydropyran-4-yl)benzamide; cc-69; SCHEMBL373524; SCHEMBL17926774; CTK8C0589; DTXSID70196444; EX-A122; AOB2606
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7280 nM
External Link
CID: 10202642
TTD: D0C3AD
 Compound Name IN-1166 Investigative [28]
Synonyms
UNII-86NAB50A9A; CHEMBL387748; 86NAB50A9A; SCHEMBL373674; BDBM50214857; Benzonitrile, 3-(((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)amino)-; 945244-71-3
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1030 nM
External Link
CID: 16654987
TTD: D0H6ZP
 Compound Name Oxindole 94 Investigative [32]
Synonyms
SB 202190; 152121-30-7; SB202190; SB-202190; FHPI; SB202190 (FHPI); UNII-PVX798P8GI; 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole; CHEBI:79090; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; PVX798P8GI; SB 202190, Immobilized; C20H14FN3O; Phenol, 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-; 4-[4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]phenol; 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 14.3 nM
External Link
CID: 5169
TTD: D0VC0I
 Compound Name ZM-336372 Investigative [33]
Synonyms
ZM 336372; 208260-29-1; ZM336372; 3-(dimethylamino)-N-(3-(4-hydroxybenzamido)-4-methylphenyl)benzamide; N-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide; CHEMBL186526; n-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide; 3-(dimethylamino)-N-{3-[(4-hydroxybenzoyl)amino]-4-methylphenyl}benzamide; 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]benzamide; 3-(dimethylamino)-N-[3-(4-hydroxybenzamido)-4-methylphenyl]benzamide; Bio1_001346; compound 1 [PMID: 15454231
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 180 nM
External Link
CID: 5730
TTD: D00NWF
 Compound Name ML-3375 Investigative [34]
Synonyms
CHEMBL113419; SCHEMBL4460547; SCHEMBL13712659; ZINC13491685; BDBM50119524; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridine; 2-(Methylthio)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 630 nM
External Link
CID: 9795838
TTD: D09HBZ
 Compound Name 6-o-tolylquinazolin-2-amine Investigative [35]
Synonyms
CHEMBL215952; SCHEMBL5494575; RAWAQXBVMDKSIO-UHFFFAOYSA-N; ZINC35049815
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3903 nM
External Link
CID: 16086113
TTD: D09HXU
 Compound Name ML-3403 Investigative [34]
Synonyms
p38 MAP Kinase Inhibitor III; ML3403; 549505-65-9; ML 3403; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-N-(1-phenylethyl)pyridin-2-amine; CHEMBL111364; (RS)-{4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]pyridin-2-yl}-(1-phenylethyl)amine]; K00568a; AC1O4WCF; SCHEMBL2896072; GTPL6014; ml-3043; SCHEMBL15013352; MolPort-023-278-904; HMS3229M04; {4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 380 nM
External Link
CID: 6419739
TTD: D0W4FF
 Compound Name L-779450 Investigative [36]
Synonyms
303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9950176
TTD: D06WJA
 Compound Name ML-3163 Investigative [37]
Synonyms
ML 3163; CHEMBL111456; 4-[5-(4-Fluorophenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-3H-imidazol-4-yl]pyridine; SCHEMBL4106398; BDBM50114690; IN1229; 4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine; 4-(2-(4-(methylsulfinyl)benzylthio)-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridine
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4000 nM
External Link
CID: 9845197
TTD: D08DSJ
 Compound Name KT-5720 Investigative [38]
Synonyms
KT 5720; KT5720; 108068-98-0; GTPL337; ZINC3873013; KT 5720, &gt; hexyl (15R,16R,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3 inverted exclamation marka,2 inverted exclamation marka,1 inverted exclamation marka-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-c
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 454202
TTD: D0G2VC
 Compound Name PD-0173956 Investigative [39]
Synonyms
UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 50 nM
External Link
CID: 5330524
TTD: D0GW4Q
 Compound Name PD-0166326 Investigative [39]
Synonyms
PD-166326
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 140 nM
External Link
CID: 447700
TTD: D0P3JW
DrugBank: DB08339
 Compound Name STAUROSPORINONE Investigative [38]
MOA Inhibitor
External Link
TTD: D0GB4V
 Compound Name Ro31-8220 Investigative [38]
Synonyms
Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5083
TTD: D0M5FF
 Compound Name KN-62 Investigative [38]
Synonyms
KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5312126
TTD: D0N6ES
 Compound Name CI-1040 Investigative [38]
MOA Inhibitor
External Link
CID: 6918454
TTD: D0B9BU
DrugBank: DB12429
 Compound Name 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative [40]
Synonyms
4,5,6,7-tetrabromobenzotriazole
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 1694
TTD: D0O1YH
DrugBank: DB04462
 Compound Name B-Octylglucoside Investigative [14]
Synonyms
29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 62852
TTD: D02UVH
 Compound Name 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative [41]
MOA Inhibitor
External Link
CID: 9859248
TTD: D0A5RM
 Compound Name Bisindolylmaleimide-I Investigative [38]
Synonyms
Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 2396
TTD: D0TO6S
DrugBank: DB03777
 Compound Name RO-316233 Investigative [38]
Synonyms
119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 2399
TTD: D0L8HO
2B91: Colorectal cancer 25 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Retifanlimab Approved [42]
Synonyms
INCMGA0012; Retifanlimab
    Click to Show/Hide
External Link
TTD: D0PG5O
 Compound Name Aflibercept Approved [43]
Synonyms
Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
    Click to Show/Hide
External Link
TTD: D0C9ET
 Compound Name Regorafenib Approved [44]
Synonyms
755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
    Click to Show/Hide
External Link
CID: 11167602
TTD: D09GDD
DrugBank: DB08896
 Compound Name Bevacizumab Approved [45]
Synonyms
Bevacizumab (ophthalmic slow-release tissue tablet)
    Click to Show/Hide
External Link
TTD: D04KBL
 Compound Name SYM-004 Phase 3 [45]
Synonyms
Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
    Click to Show/Hide
External Link
TTD: D0CR8H
 Compound Name Bevacizumab + Erlotinib Phase 3 [46]
External Link
TTD: D09BKY
 Compound Name CPI-613 Phase 3 [45]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Bevacizumab Approved [43]
External Link
TTD: D0FX3U
 Compound Name AlloStim Phase 2/3 [47]
Synonyms
AlloStim (TN)
    Click to Show/Hide
External Link
TTD: D0B3CC
 Compound Name Sibrotuzumab Phase 2 [48]
External Link
TTD: DVX3H0
 Compound Name CV301 Phase 2 [49]
External Link
TTD: D9LT5G
 Compound Name Efatutazone Phase 2 [50]
Synonyms
Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione
    Click to Show/Hide
External Link
CID: 9832447
TTD: D0Y8NZ
DrugBank: DB11894
 Compound Name LOR-2040 Phase 2 [51]
External Link
TTD: D0I7NG
 Compound Name RG7221 Phase 2 [52]
External Link
TTD: D06FTM
 Compound Name PEG-SN38 Phase 2 [53]
Synonyms
EZN-2208
    Click to Show/Hide
External Link
CID: 59443782
TTD: D05UFP
 Compound Name MEGF0444A Phase 2 [54]
External Link
TTD: D01LES
 Compound Name Encapsulated cell therapy Phase 1/2 [55]
External Link
TTD: D0XY8C
 Compound Name AB928 Phase 1/2 [56]
External Link
CID: 135242184
TTD: D04UBI
 Compound Name MGD007 Phase 1 [52]
External Link
TTD: D00PEN
 Compound Name BNC-101 Phase 1 [57]
External Link
TTD: DD6AZ5
 Compound Name Navicixizumab Phase 1 [45]
External Link
TTD: D00IVN
 Compound Name RG7160 Discontinued in Phase 2 [58]
External Link
TTD: D0E2CQ
 Compound Name Nimesulide Terminated [59]
Synonyms
51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin
    Click to Show/Hide
External Link
CID: 4495
TTD: D0C0JT
DrugBank: DB04743
 Compound Name Saracatinib Phase 2 [60]
External Link
CID: 10302451
TTD: D05YTN
DrugBank: DB11805
 Compound Name G3139 + Irinotecan Investigative [61]
External Link
CID: 91865905
TTD: D05IAN
References
Ref 1 LINC01605, regulated by the EP300-SMYD2 complex, potentiates the binding between METTL3 and SPTBN2 in colorectal cancer. Cancer Cell Int. 2021 Sep 20;21(1):504. doi: 10.1186/s12935-021-02180-8.
Ref 2 m(6)A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways. Onco Targets Ther. 2019 Jun 4;12:4391-4402. doi: 10.2147/OTT.S201052. eCollection 2019.
Ref 3 Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11.
Ref 4 Clinical pipeline report, company report or official report of FORMA Therapeutics.
Ref 5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
Ref 6 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41. doi: 10.1002/art.24485.
Ref 7 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. doi: 10.1016/s0165-6147(00)01865-4.
Ref 8 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014). Expert Opin Ther Pat. 2015;25(8):849-72. doi: 10.1517/13543776.2015.1039984. Epub 2015 May 19.
Ref 9 Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem. 2010 Mar 25;53(6):2345-53. doi: 10.1021/jm9012906.
Ref 10 Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38Alpha mitogen-activated protein kinase. J Med Chem. 2011 Apr 14;54(7):2255-65. doi: 10.1021/jm101423y. Epub 2011 Mar 4.
Ref 11 Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum. 2003 Sep;48(9):2670-81. doi: 10.1002/art.11227.
Ref 12 Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4433-7. doi: 10.1016/j.bmcl.2008.06.028. Epub 2008 Jun 12.
Ref 13 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 14 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 15 The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. Blood. 2001 Aug 1;98(3):667-73. doi: 10.1182/blood.v98.3.667.
Ref 16 Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. doi: 10.1021/jm0408767.
Ref 17 Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9. doi: 10.1016/j.bmcl.2005.08.038. Epub 2005 Sep 19.
Ref 18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499).
Ref 19 In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218. doi: 10.1016/j.bmc.2010.01.070. Epub 2010 Feb 8.
Ref 20 Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013 Sep;13(9):679-92. doi: 10.1038/nri3495. Epub 2013 Aug 19.
Ref 21 Amide-based inhibitors of p38alpha MAP kinase. Part 2: design, synthesis and SAR of potent N-pyrimidyl amides. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2560-3. doi: 10.1016/j.bmcl.2010.02.090. Epub 2010 Mar 2.
Ref 22 Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. J Med Chem. 2006 Mar 9;49(5):1562-75. doi: 10.1021/jm050736c.
Ref 23 Novel triazolopyridylbenzamides as potent and selective p38Alpha inhibitors. Bioorg Med Chem Lett. 2012 May 15;22(10):3431-6. doi: 10.1016/j.bmcl.2012.03.099. Epub 2012 Apr 4.
Ref 24 The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4666-70. doi: 10.1016/j.bmcl.2005.07.076.
Ref 25 Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3745-8. doi: 10.1016/j.bmcl.2008.05.037. Epub 2008 May 16.
Ref 26 Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem. 2005 Sep 22;48(19):5966-79. doi: 10.1021/jm050165o.
Ref 27 Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett. 2005 Nov 15;15(22):5095-9. doi: 10.1016/j.bmcl.2005.06.083.
Ref 28 Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4006-10. doi: 10.1016/j.bmcl.2008.06.007. Epub 2008 Jun 6.
Ref 29 Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5389-94. doi: 10.1016/j.bmcl.2004.08.007.
Ref 30 Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50. doi: 10.1016/s0960-894x(02)01020-x.
Ref 31 Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orall... J Med Chem. 2006 Apr 6;49(7):2210-21.
Ref 32 Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc Res. 2003 Oct 1;59(4):893-900. doi: 10.1016/s0008-6363(03)00509-1.
Ref 33 A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5383-7. doi: 10.1016/j.bmcl.2004.08.006.
Ref 34 Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. doi: 10.1021/jm030766k.
Ref 35 Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86. doi: 10.1021/jm0605482.
Ref 36 The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. doi: 10.1016/j.bmcl.2005.09.072. Epub 2005 Nov 2.
Ref 37 From imidazoles to pyrimidines: new inhibitors of cytokine release. J Med Chem. 2002 Jun 20;45(13):2733-40. doi: 10.1021/jm011098a.
Ref 38 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. doi: 10.1042/0264-6021:3510095.
Ref 39 Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. doi: 10.1016/j.bmcl.2009.10.085. Epub 2009 Oct 23.
Ref 40 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. doi: 10.1021/jm049854a.
Ref 41 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. doi: 10.1021/jm0605740.
Ref 42 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 43 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 44 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891).
Ref 45 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 46 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Ref 47 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 48 ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 49 ClinicalTrials.gov (NCT03547999) A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC. U.S. National Institutes of Health.
Ref 50 ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
Ref 51 ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 52 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 53 ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 55 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 56 ClinicalTrials.gov (NCT04660812) An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 57 ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)
Ref 59 Clinical pipeline report, company report or official report of Genentech (2011).
Ref 60 Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
Ref 61 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.